This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
SAN DIEGO — Cancer vaccines have traveled a potholed road over the last decade. But as researchers from different companies and academic institutions presented promising early data at the American Association for Cancer Research annual meeting in San Diego this week, experts said there’s a collective feeling of turning a corner. “There’s a lot more interest in vaccines” now that the technology is improving, said Roy Herbst, chief of medical oncology at Yale Can
Vertex Pharmaceuticals will buy Alpine Immune Sciences, a maker of protein-based medicines that harness the immune system, for $4.9 billion, the companies announced Wednesday. It is the largest acquisition in Vertex’s history. The acquisition gives Vertex a drug called povetacicept, which has shown promise in treating IgA nephropathy (IgAN), an autoimmune disorder of the kidney that can lead to end-stage renal disease and affects 130,000 people in the U.S.
Recent biotech company acquisitions have put emerging schizophrenia treatments in focus. But many development hurdles still stand in the way of new medicines for the brain.
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
In an era when huge price hikes for prescription drugs are almost guaranteed to draw criticism, is there any circumstance when a 486% increase for a medicine might appear to be justified? A small company called Harrow argues that it can make the case for an injectable eye treatment that has been used to combat several serious conditions. Company executives maintain the medication, which has been largely out of stock for the past few years, requires substantial investment in order to restore a st
SAN DIEGO — Kimryn Rathmell, director of the National Cancer Institute, gestured toward the screen and asked an audience of clinicians, researchers, and patient advocates what they thought they were looking at. Projected behind her was a patchwork of purple, red, pink, and blue squares. Moments later, a larger-than-life image of Taylor Swift flashed in the middle of the pattern, and laughter rippled through the room here at the American Association for Cancer Research annual meeting as at
The number of ongoing and active drug shortages in the U.S. stood at 323 during the fourth quarter of last year — the highest figure reached since such data began being tracked in 2001 — underscoring growing concerns about patient harm across the country. Unresolved shortages have, in fact, been hovering above 300 for more than a year as numerous basic and life-saving medicines are in short supply.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
WASHINGTON — The biotech industry’s largest trade group has parted ways with its top lobbyist, the group confirmed to STAT, adding to a recent bout of organizational tumult. The departure of Nick Shipley may be part of a greater shake-up spearheaded by the Biotechnology Innovation Organization’s new CEO, John Crowley, who took over in December.
The first medicine approved for PPD, Sage’s Zulresso, never gained traction. The company is in the midst of launching its second, but long-standing challenges could slow uptake.
The widespread attention to the recent revelations of cancer diagnoses by Princess Catherine , actress Olivia Munn , and King Charles , among others, demonstrate yet again that cancer is a feared disease. For good reason: It is a cruel killer, the second leading cause of death in the U.S. and a top killer around the world. So public faith in cancer screening (checking seeming healthy people for signs of hidden disease) is deep, driven by the widespread understanding that finding cancer early &#x
Government and regulators must ‘clearly communicate’ the extent of community pharmacists’ responsibilities when asked to dispense privately prescribed puberty suppressing hormones to children and young people, an independent review has said. The final report of the Cass review, published today, called for measures to reduce inappropriate overseas prescribing of puberty suppressing hormones.
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
The U.S. Department of Justice filed a lawsuit accusing Regeneron Pharmaceuticals of manipulating Medicare pricing by inflating the average sales price for its expensive and widely prescribed Eylea treatment for serious eye disease. In its lawsuit, the Justice Department claimed the company failed for more than a decade to report how it paid “hundreds of millions of dollars” to subsidize Eylea purchases by reimbursing drug distributors for credit-card processing fees.
Suicide is the second leading cause of death among children aged 10 to 14 in the U.S. That’s evidence of a systemic failure in identifying and addressing mental health concerns in young people. Compounding the problem is the average delay of 11 years between the onset of a mental health condition and its diagnosis. Think about it: a child exhibiting signs of mental health challenges at age 6 may not receive proper diagnosis or treatment until age 17.
Discover how Sunshine transparency reporting can be simplified, streamlined, and secured for emerging pharmaceutical companies with a focus on Healthcare Professionals (HCP) and Healthcare Organisations (HCO).
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far, so we are determined to hang on for another couple of days. And why not? The alternatives — at least those we can identify — are not so appetizing. And what better way to make the time fly than to keep busy.
Dr Reddy’s Laboratories announced the launch of the drug-free non-invasive migraine management wearable device Nerivio in Germany through its step-down subsidiary betapharm. The launch marks the company’s entry into digital therapeutics in Europe. Nerivio is approved by the United States Food and Drug Administration (USFDA), and is CE-mark certified in Europe.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello! Today, we get some optimism from the new director of the National Cancer Institute, despite a brain drain playing out in the industry and stagnant funding numbers. Also, advocates press the federal government to encourage manufacturing for the prostate cancer drug Xtandi.
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
Nine independent expert members (IEMs) have been appointed to the UK Pharmacy Professional Leadership Advisory Board. The UK-wide advisory board was set up last year with the aim of supporting and enabling collaborative working between organisations representing pharmacists and pharmacy technicians in different settings. The four UK chief pharmaceutical officers (CPhOs) then embarked on a […] The post Independent experts recruited to UK pharmacy leadership board appeared first on The Pharm
The company said the pause is necessary to meet regulatory limits on nitrosamine, but added it will not affect commercial supply nor regulatory review of the drug in early breast cancer.
If manufacturers cannot ensure safe, cost-effective delivery of treatments for rare diseases, access will remain a challenges for many patients living with these conditions.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
363 
Let's personalize your content